Replies to post #279996 on Avid Bioservices Inc (CDMO)

[biopharm]

"This is to be separated from what PPHM gets out of the trial, never the less, that will speed up things in future and work towards better clinical trial design (biomarker usage) and apart from the fact that Sunrise demonstrated again that bavituximab works (even though not approved for trial regulation reasons)."

I agree with that corp and it was the goal of the trial to gain FDA approval and remember, Joe Shan said they had protocols built into the trial design that was set up with the FDA. I'm sure Robert Garnick knew there was a chance that Opdivo would be approved before Sunrise completed and what happens then?? Some patients leave the Sunrise trial in order to hop on over to the Opidvo trial but I just hope patients were informed that Opdivo had like a 20-30% response rate and Opdivo had no biomarker test to even verify if the patients would respond! Now that is horrendous to have a drug like Opdivo approved with no biomarker...

Peregrine will have the biomarkers all lined up and ready to go before BMY.

Hmmm, but you know what.... I imagine others in Big Pharma are afraid to spell out some of their biomarkers, because it will likely FURTHER SUPPORT PS TARGETING

for example: MDSC's... : )

[JJ1223]

Science does not fail, it advances and learns...much the way cancer adapts within the human body. The knowledge surrounding Bavituximab, its MOA, and applications, continues to spread around the world. Cancer may never be completely beaten, but will be contained. PPHM will be part of the solution. GLTA